A multicentric single-arm phase II clinical trial to evaluate safety and efficacy of the combination of olaparib and PLD for platinum resistant ovarian primary peritoneal carcinoma and fallopian tube cancer patients: The GEICO-1601 ROLANDO trial—A trial in resistant ovarian cancer with olaparib and pegylated liposomal doxorubicin.

Abstract

TPS5610Background: Olaparib is a PARP-inhibitor that has demonstrated efficacy in ovarian cancer in both platinum-sensitive and platinum-resistant relapse. BRCA mutations have been identified as an...